Stallergenes Greer Ends Commercialization of Palforzia Peanut Allergy Treatment in US
Commercialization of Palforzia ended on July 31, 2026, following a voluntary discontinuation by Stallergenes Greer.
3 reports on this incident · first at Aug 19, 2026, 7:41 a.m. ET
Earlier reports
Aug 19, 2026, 7:53 a.m. ET
Stallergenes Greer Discontinues Palforzia Peanut Allergy Treatment in US
Commercialization of Palforzia ended on July 31, 2026, with production winding down in phases, and the product is no longer available for commercial distribution in the United States, medicaldaily.com reported. Palforzia is an oral immunotherapy approved by the FDA for confirmed peanut allergy in children ages 1 through 17. Stallergenes Greer initiated the voluntary discontinuation due to complex administrative and dosing requirements that contributed to limited adoption in clinical practice, medicaldaily.com reported. The decision was not related to product safety, quality, or efficacy. Patients are advised not to stop, restart, or change a dose on their own, according to medicaldaily.com.
Aug 19, 2026, 7:41 a.m. ETFirst report
Stallergenes Greer Discontinues Palforzia Peanut Allergy Treatment in US
Commercialization of Palforzia ended on July 31, 2026, in a developing situation reported by Medical Daily. The product is no longer available for commercial distribution in the United States. Palforzia, manufactured by Stallergenes Greer, is an oral immunotherapy approved by the FDA for confirmed peanut allergy in children ages 1 through 17. Medical Daily reported that the voluntary discontinuation is not related to product safety, quality, or efficacy. Instead, complex administrative and dosing requirements contributed to limited adoption in clinical practice, with production now winding down in phases. Regarding treatment, patients should not stop, restart, or change a dose on their own.
Was this report accurate and useful?
Sources
Revision history
- Version 119 Aug 2026, 12:23current
First published.
- Version 119 Aug 2026, 11:41current
First published.
- Version 119 Aug 2026, 11:53current
First published.
How we work
This site models an investigative reporter rather than a wire desk. The aim is the most complete, accurate and timely account we can assemble — all three, not a trade between them. Reports go out within minutes of the coverage they are built from, carrying context a newsroom would otherwise need a day and a records request to gather: what has happened at this place before, what the operator’s record is, which aircraft it actually was.
Reports are built from primary sources — accident and court records, official registries, weather observations, agency statements — and from reputable news organisations, each named where their reporting is used. Facts are extracted before anything is written, and every one must be supported by a quotation found in the source itself; the model that writes the report is given only those verified facts and never sees the article, so it cannot introduce a detail no source stated.
Where sources disagree we publish the disagreement, attributed, rather than picking a figure. Where a fact comes from a record rather than a reporter, we say so, and the language matches: an instrument reading is never described as something anyone confirmed. Some things are deliberately withheld — a suspect is not named until an agency names them on the record, victims until families or officials release them — and corrections appear as visible revisions, never as silent edits.
None of that makes a report true. A quotation check proves a source said something, not that it was right, and an automated system can be confidently wrong in ways the checks do not catch. If something here is wrong, the feedback above is how it gets found. The full methodology, including what we refuse to publish.